[HTML][HTML] The oxindole/imidazole derivative C16 reduces in vivo brain PKR activation
S Ingrand, L Barrier, C Lafay-Chebassier… - FEBS letters, 2007 - Elsevier
S Ingrand, L Barrier, C Lafay-Chebassier, B Fauconneau, G Page, J Hugon
FEBS letters, 2007•ElsevierInhibition of double-stranded RNA-dependent protein kinase (PKR) represents an
interesting strategy for neuroprotection. However, inhibiting this kinase which triggers the
apoptotic process could favour in counterpart cell proliferation and tumorigenesis. Here, we
use an in vivo model of 7-day-old rat displaying a high activation of brain PKR to investigate
the effects of a new PKR inhibitor identified as an oxindole/imidazole derivative (C16). We
show for the first time that acute systemic injection of C16 specifically inhibits the apoptotic …
interesting strategy for neuroprotection. However, inhibiting this kinase which triggers the
apoptotic process could favour in counterpart cell proliferation and tumorigenesis. Here, we
use an in vivo model of 7-day-old rat displaying a high activation of brain PKR to investigate
the effects of a new PKR inhibitor identified as an oxindole/imidazole derivative (C16). We
show for the first time that acute systemic injection of C16 specifically inhibits the apoptotic …
Inhibition of double-stranded RNA-dependent protein kinase (PKR) represents an interesting strategy for neuroprotection. However, inhibiting this kinase which triggers the apoptotic process could favour in counterpart cell proliferation and tumorigenesis. Here, we use an in vivo model of 7-day-old rat displaying a high activation of brain PKR to investigate the effects of a new PKR inhibitor identified as an oxindole/imidazole derivative (C16). We show for the first time that acute systemic injection of C16 specifically inhibits the apoptotic PKR/eIF2α signaling pathway without stimulating the proliferative mTOR/p70S6K signaling mechanism.
Elsevier